clinical trials
-
Research updates, April 7
A clinical trial for non-invasive vagal nerve stimulation failed in improving fatigue in Long COVID. 45 participants used a specific transcutaneous auricular vagus nerve stimulation (taVNS) device, or a sham (placebo), during the four-week trial.
-
Research updates, March 31
The heart failure drug Ivabradine did not significantly improve symptoms for people with Long COVID and postural orthostatic tachycardia syndrome (POTS), according to preliminary results that RECOVER researchers recently shared at a conference.
-
Research updates, March 24
More than 150,000 deaths from COVID-19 went uncounted in the U.S. in the first two years of the pandemic, according to a new study in Science Advances. Researchers used machine learning to evaluate death certificates from March 2020 to December 2021, and estimated that 19% more COVID-19 deaths occurred than originally reported.
-
Research updates, March 10
A large retrospective cohort study found significant healthcare cost increases for Long COVID over five years. The study was shared as a preprint in medRxiv and included the records of over 143,000 people.
-
Research updates, March 3
Researchers identified high levels of cytokine interferon gamma (IFN-γ) in white blood cells as a potential biomarker for Long COVID. The small study, published in Science Advances, found that symptoms improved when production of IFN-γ (a molecule that plays an important role in immune response) decreased.
-
Research updates, February 17
A new review in Dovepress states that Long COVID, myalgic encephalomyelitis (ME), and postural orthostatic tachycardia syndrome (POTS) should be classified as neuroimmune disorders.
-
Research updates, February 10
A large study recently connected “chronic absenteeism” to pediatric Long COVID, further disproving the “immunity debt” talking points from pundits earlier in the pandemic.
-
Long COVID affects millions of children. The largest pediatric trial so far launches this year.
One NIH study will test low-dose naltrexone, while other upcoming trials will test larozitide and taurine.
-
Research updates, February 3
The Food and Drug Administration (FDA) has granted expanded access to the stem cell infusion RegeneCyte for Long COVID.
-
Research updates, January 27
A large prospective cohort study published in Infectious Diseases found that a majority of people with Long COVID did not recover.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
-
Alice Wong showed us Disability Justice makes our advocacy stronger
-
“The Way Disabled People Love Each Other”: In conversation with Leah Lakshmi Piepzna-Samarsinha
-
I moved into a tiny home in the woods after getting Long COVID.
-
Two Long COVID short films premiere at the Easterseals Disability Film Challenge
-
National COVID-19 trends, April 7
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance